Scrip
Blurring the boundaries between regulatory approval and HTAs
16 September 2009
Ian Schofield
Once there was a clear distinction between the scientific evaluation of new drugs and the assessment of their value for use in reimbursement decisions. The latter was often referred to as the “fourth hurdle”, and took place after quality, safety and efficacy had been assessed and the product approved....
Please Login to read the full article.
16 September 2009
Ian Schofield
Please Login to read the full article.
RELATED CONTENT
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
